Corcept Therapeutics CORT
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$14.66M (5 inflow days, 15 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 30.4% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 8.97% to 8.44% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| D. E. Shaw & Co., L.P. | Hedge Fund | 2026/Q4 | +1,041,272 | 1.8% |
| AQR Capital Management | Hedge Fund | 2026/Q4 | +1,038,815 | 3.3% |
| Jane Street Group, LLC | Private Company | 2026/Q4 | +757,074 | 0.7% |
| Federated Hermes, Inc. | Mutual Fund | 2026/Q4 | +421,742 | 0.4% |
| Two Sigma Investments, LP | Hedge Fund | 2026/Q4 | +295,600 | 0.8% |
| Hudson River Trading LLC | Private Company | 2026/Q4 | +271,149 | 0.4% |
| Barclays PLC | Public Company | 2026/Q4 | +244,925 | 0.3% |
| Bridgewater Associates | Hedge Fund | 2026/Q4 | +210,578 | 0.2% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q4 | +185,080 | 4.5% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q4 | +165,998 | 0.3% |
| FMR | Mutual Fund | 2026/Q4 | +151,025 | 3.2% |
| California Public Employees' Retirement System | Government Pension Fund | 2026/Q4 | +139,533 | 0.1% |
| Citadel Advisors LLC | Hedge Fund | 2026/Q4 | +130,713 | 0.2% |
| Northern Trust Global Investments | Mutual Fund | 2026/Q4 | +123,995 | 0.8% |
| Jacobs Levy Equity Management Inc | Mutual Fund | 2026/Q4 | +106,926 | 0.7% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 9 Nov 2026 | Daniel Swisher | Independent Director | Derivative Exercise and Sale | -1,500 | $74.07 | – |
| 2 Nov 2026 | Sean Maduck | Former President of Endocrinology | Derivative Exercise and Sale | -25,000 | $82.68 | 129,593 |
| 1 Nov 2026 | Roberto Vieira | President of Oncology | Derivative Exercise and Sale | -8,333 | $81.52 | 3,946 |
| 14 Oct 2026 | James Wilson | Independent Chairperson | Automatic Disposition | -10,000 | $116.30 | 1,454,543 |
| 1 Oct 2026 | Roberto Vieira | President of Oncology | Derivative Exercise and Sale | -8,333 | $116.59 | 3,946 |
| 1 Oct 2026 | Sean Maduck | Former President of Endocrinology | Derivative Exercise and Sale | -25,000 | $116.55 | 119,655 |
| 1 Oct 2026 | Joseph Lyon | Chief Technology & Accounting Officer | Derivative Exercise and Sale | -10,000 | $116.54 | 5,683 |
| 30 Sep 2026 | Joseph Lyon | Chief Technology & Accounting Officer | Intent to Sell (Form 144) | -10,000 | $115.23 | – |
| 30 Sep 2026 | Justin Gunn | President of Endocrinology | Other Derivative Acquisition | +100,000 | $114.03 | 100,000 |
| 30 Sep 2026 | Justin Gunn | President of Endocrinology | Initial Statement of Beneficial | +0 | – | 6,965 |
| 23 Sep 2026 | Gary Robb | Chief Business Officer & Secretary | Other Acquisition | +10,000 | – | 94,914 |
| 23 Sep 2026 | Gary Robb | Chief Business Officer & Secretary | Other Disposition | -17,100 | – | 94,914 |
| 16 Sep 2026 | Gary Robb | Chief Business Officer & Secretary | Derivative Exercise and Retained | +17,493 | $8.27 | 102,014 |
| 15 Sep 2026 | Roberto Vieira | President of Oncology | Automatic Disposition | -296 | $100.82 | 3,946 |
| 14 Sep 2026 | James Wilson | Independent Chairperson | Automatic Disposition | -10,000 | $111.70 | 1,464,543 |
| 13 Sep 2026 | Joseph Lyon | Chief Technology & Accounting Officer | Derivative Exercise and Sale | -10,000 | $114.12 | 5,683 |
| 1 Sep 2026 | Atabak Mokari | Chief Financial Officer | Sale to Issuer | -102 | $113.38 | 16,304 |
| 1 Sep 2026 | Gary Robb | Chief Business Officer & Secretary | Sale to Issuer | -91 | $113.38 | 84,521 |
| 1 Sep 2026 | Sean Maduck | Former President of Endocrinology | Sale to Issuer | -117 | $113.38 | 119,655 |
| 1 Sep 2026 | Joseph Lyon | Chief Technology & Accounting Officer | Sale to Issuer | -72 | $113.38 | 5,683 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 9,125,717 | 8.4% | 8.1 |
| 15 Oct 2026 | 8,588,418 | 7.9% | 12.3 |
| 30 Sep 2026 | 8,540,393 | 7.9% | 3.6 |
| 15 Sep 2026 | 9,350,914 | 8.7% | 9.9 |
| 31 Aug 2026 | 9,399,154 | 8.7% | 11.9 |
| 14 Aug 2026 | 9,696,757 | 9.0% | 10.5 |
No comments yet — be the first to weigh in on CORT.
Sign in to join the discussion.